Tysabri Return Depends On Patient Group Input, CDER Deputy Says
Executive Summary
FDA will rely on the input of multiple sclerosis patient organizations to help determine the status of Biogen Idec/Elan's Tysabri, Center for Drug Evaluation & Research Acting Deputy Director Douglas Throckmorton told the Stanford Washington Research Group conference May 5